Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C38H60O18 |
| Molecular Weight | 804.8722 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 21 / 21 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CCC[C@](C)([C@H]1CC[C@@]34CC(=C)[C@@](C3)(CC[C@@H]24)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(=O)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=UEDUENGHJMELGK-HYDKPPNVSA-N
InChI=1S/C38H60O18/c1-16-11-37-9-5-20-35(2,7-4-8-36(20,3)34(50)55-32-29(49)26(46)23(43)18(13-40)52-32)21(37)6-10-38(16,15-37)56-33-30(27(47)24(44)19(14-41)53-33)54-31-28(48)25(45)22(42)17(12-39)51-31/h17-33,39-49H,1,4-15H2,2-3H3/t17-,18-,19-,20+,21+,22-,23-,24-,25+,26+,27+,28-,29-,30-,31+,32+,33+,35-,36-,37-,38+/m1/s1
| Molecular Formula | C38H60O18 |
| Molecular Weight | 804.8722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 21 / 21 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Stevioside is an ent-kaurene type diterpenoid glycoside isolated
from leaves of Stevia rebaudiana (Bertoni) Bertoni, a
perennial herb of the asteraceae (compositae) family.
Stevioside and related compounds are responsible for the
sweet taste of Stevia leaves. Stevioside is an intense sweetener and
the extract of its source (S. rebaudiana) finds extensive use in
countries like Japan, China, Russia, Korea, Paraguay,
Argentina, Indonesia, Malaysia, Australia, New Zealand,
South America, and others, to sweeten local teas, medicines,
food, and beverages. Stevia leaves are also in use
for their medicinal benefits in hypertension, obesity, topical
dressing for wounds, and other skin disorders. Oral stevioside is not taken up by the human body (or
the uptake is extremely low) and none of the digestive
enzymes from the gastro-intestinal tract of different animals
and human body are able to degrade stevioside into steviol. A number of studies have suggested that, beside sweetness, stevioside along with related compounds, which include rebaudioside A, steviol and isosteviol may also offer therapeutic benefits, as they have anti-hyperglycemic, anti-hypertensive, anti-inflammatory, anti-tumor, anti-diarrheal, diuretic, and immunomodulatory actions.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21213347
Curator's Comment: Stevioside and rebaudioside were first isolated by two French chemists, Bridel and Lavielle.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
500 mg 3 times / day multiple, oral Studied dose Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Nausea alone, Dizziness... AEs leading to discontinuation/dose reduction: Nausea alone (1 pt) Sources: Dizziness (1 pt) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Dizziness | 1 pt Disc. AE |
500 mg 3 times / day multiple, oral Studied dose Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea alone | 1 pt Disc. AE |
500 mg 3 times / day multiple, oral Studied dose Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29655729/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29655729/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29655729/ |
no | |||
| no | ||||
| no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29655729/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29655729/ |
no | |||
| no | ||||
| no | ||||
| weak [IC50 62.6 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29655729/ |
weak | |||
| yes [IC50 11.1 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [Km 12.5 uM] | ||||
| yes [Km 6.9 uM] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: a transcriptomic and metabolomic study. | 2015-03 |
|
| Antiamnesic effect of stevioside in scopolamine-treated rats. | 2010-06 |
|
| Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991-01-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21213347
Stevioside was administered at a dose of 250 mg thrice a day for 1 year to 60 hypertensive volunteers. After 3 months the systolic and diastolic blood pressure decreased significantly and the effect was also found to be persisting.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21213347
High concentrations of stevioside (2–5 uM) and steviol
(0.2–0.8 uM) were observed to decrease cell viability in
T84, Caco-2, and HT29 cells (assayed by MTT method).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:43:10 GMT 2025
by
admin
on
Mon Mar 31 19:43:10 GMT 2025
|
| Record UNII |
0YON5MXJ9P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
JECFA EVALUATION |
INS-960
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
||
|
DSLD |
2560 (Number of products:5)
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-960
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000176630
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
0YON5MXJ9P
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
DTXSID7021281
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
C012043
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
SUB191567
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
57817-89-7
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
0YON5MXJ9P
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
37106
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
260-975-5
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
9271
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
1622408
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
442089
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
Stevioside
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | |||
|
m10209
Created by
admin on Mon Mar 31 19:43:10 GMT 2025 , Edited by admin on Mon Mar 31 19:43:10 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
MIC value of the in vitro growth of Mycobacterium Tuberculosis (H37RV strain) of the new anti-tuberculosis terpenoid derived agent tested was 7.5 ug/ml.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |